SCHEMBL21765873

SCHEMBL21765873

CC(C)CC(=O)Nc1ccc(NC(=O)CC(C)C)cc1

nearest known ligand 0.88

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.88
LMNA P02545 2/20 0.76
HPGD P15428 2/20 0.76
SMN1; SMN2 Q16637 7/20 0.69
RAB9A P51151 6/20 0.69
NPC1 O15118 4/20 0.69
MAPT P10636 1/20 0.67
MAPK1 P28482 1/20 0.67
GAA P10253 2/20 0.66
ALDH1A1 P00352 2/20 0.63
KDM4E B2RXH2 1/20 0.62
TSHR P16473 1/20 0.62
MTNR1B P49286 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.56
GFER P55789 1/20 0.56
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
ADORA2A P29274 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6389276 0.92 PTPN1 (0.76) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL8361578 0.92 PTPN1 (0.76) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL13129132 0.90 PTPN1 (0.73) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL12018050 0.90 PTPN1 (0.73) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL12560201 0.90 PTPN1 (0.73) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL24485239 0.90 RAB9A (0.79) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL7655640 0.90 PTPN1 (0.73) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL24897530 0.90 PTPN1 (0.73) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL12197967 0.90 PTPN1 (0.73) PTPN1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL7402722 0.90 PTPN1 (0.73) PTPN1LMNAHPGDSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-20230146870-A1 METHOD TO QUANTIFY AFFINITY AND SELECTIVITY OF SMALL MOLECULES FOR PROTEINS IN LIVING CELLS OHIO STATE INNOVATION FOUNDATION 2023-05-11 US disclosed
WO-2020041270-A1 COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF FOG PHARMACEUTICALS, INC. (US) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms CRBN, CD4, CD74 PTPN1 1523/4885LMNA 4557/4885HPGD 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.